Rusty Close, Douglas Gray, Brent Hoard, and Joseph Kadlec published the November 11, 2026, Reuters Legal News article, “How Clinical Integration Is Impacting Deal Terms for AI-Enabled Medical Devices.”

As AI-powered medical devices increasingly become a critical part of clinical workflows, these technologies are presenting new opportunities for strategic buyers. In 2025, the Food and Drug Administration cleared 295 AI/ML-enabled medical devices, and that number is expected to grow in the years to come.

However, as strategic buyers compete for this cutting-edge technology — particularly those devices embedded in the clinical ​workflow — they also face new acquisition challenges. From deal structuring to diligence, acquirers must evaluate unique and evolving considerations to mitigate risk and ensure a successful transaction.

Read the full article on Reuters.